ArticleCureus2026
Timing and Resolution of Bothersome Hot Flashes Following Short Course Oral Gonadotropin-Releasing Hormone Receptor Antagonist Relugolix, and Stereotactic Body Radiotherapy for Localized Prostate Cancer.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Androgen deprivation therapy (ADT) has been shown to improve cancer control when combined with radiation therapy. Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, suppresses testosterone, causing several hormonally related symptoms that resolve with testosterone recovery. Hot flashes are particularly bothersome. This study sought to evaluate the timeline of hot flashes following a short course of relugolix, and stereotactic body radiotherapy (SBRT) for unfavorable localized prostate cancer. Methods IRB approval was obtained for retrospective review of prospectively collected data. Patients were treated at MedStar Georgetown University Hospital per an institutional protocol. Hot flashes were self-reported via question 13a of the Expanded Prostate Index Composite (EPIC)-26 before relugolix initiation, the first day of SBRT treatment, and at subsequent follow-up visits. All patients were treated with the robotic SBRT (Accuray Inc.). Total testosterone levels were measured before SBRT and at each follow-up. Results From January 2021 to September 2023, 89 localized prostate cancer patients (63 intermediate, 20 high-risk, and 6 recurrent) at a median age of 72 years (range 49-93) were treated with a short course of relugolix (average 6.25 months, range 3-29 months) and prostate SBRT. The median time to cessation of hot flashes was around nine-months post-SBRT when the median testosterone had recovered in 56% (50) of patients, with a median testosterone of 230 ng/dL. The incidence of burdensome hot flashes (a moderate to big problem) returned to baseline nine-months post-SBRT (0%) with a cumulative incidence of 57% (51). The median EPIC-26 hot flash score of 98.7 declined to 49.0 at one-month post-SBRT and returned to baseline by nine-months post-SBRT. These differences were statistically significant (p< 0.01) and clinically significant (MCID=4.45). Testosterone recovery (>230 ng/dL) occurred in 97% (86) of patients 12-months post-SBRT. Conclusions Bothersome hot flashes occur in more than 50% of men treated with short-course relugolix and SBRT. Resolution of hot flashes occurs in the majority of men by nine-months post-SBRT. Hot flash resolution mirrored testosterone recovery at relatively low levels. Reassurance of the temporary nature of hot flashes may reduce patient anxiety and limit associated bother.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.